Summary
2.04 -0.01(-0.25%)05/15/2024
Cerus Corp. (CERS)
Cerus Corp. (CERS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.79 | 10.15 | -2.64 | -16.14 | 6.65 | -16.52 | -71.92 | -84.78 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.85 | |
| Open | 1.76 | |
| High | 1.88 | |
| Low | 1.76 | |
| Volume | 818,850 | |
| Change | 0.05 | |
| Change % | 2.79 | |
| Avg Volume (20 Days) | 847,892 | |
| Volume/Avg Volume (20 Days) Ratio | 0.97 | |
| 52 Week Range | 1.21 - 3.08 | |
| Price vs 52 Week High | -40.10% | |
| Price vs 52 Week Low | 52.48% | |
| Range | 4.83 | |
| Gap Up/Down | -0.07 | |
Fundamentals | ||
| Market Capitalization (Mln) | 375 | |
| EBIDTA | -17,563,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 4.40 | |
| Book Value | 0.2670 | |
| Earnings Per Share | -0.1700 | |
| EPS Estimate Current Quarter | -0.0500 | |
| EPS Estimate Next Quarter | -0.0300 | |
| EPS Estimate Current Year | -0.1300 | |
| EPS Estimate Next Year | -0.0600 | |
| Diluted EPS (TTM) | -0.1700 | |
| Revenues | ||
| Profit Marging | -0.1927 | |
| Operating Marging (TTM) | -0.2080 | |
| Return on asset (TTM) | -0.0632 | |
| Return on equity (TTM) | -0.5777 | |
| Revenue TTM | 163,758,000 | |
| Revenue per share TTM | 0.9040 | |
| Quarterly Revenue Growth (YOY) | 0.2390 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 87,094,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.0255 | |
| Revenue Enterprise Value | 2.2216 | |
| EBITDA Enterprise Value | -13.1903 | |
| Shares | ||
| Shares Outstanding | 184,890,000 | |
| Shares Float | 156,918,052 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 3.13 | |
| Institutions (%) | 74.99 | |
05/02 19:37 EST - seekingalpha.com
Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President of Regulatory and Quality Conference Call Participants Emily Christy - Stifel Jacob Johnson - Stephens Ross Osborne - Cantor Fitzgerald William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation First Quarter 2024 Earnings Conference Call.
Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President of Regulatory and Quality Conference Call Participants Emily Christy - Stifel Jacob Johnson - Stephens Ross Osborne - Cantor Fitzgerald William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation First Quarter 2024 Earnings Conference Call.
04/18 08:30 EST - businesswire.com
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Inv.
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Inv.
03/26 08:30 EST - businesswire.com
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventori.
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventori.
03/19 08:00 EST - businesswire.com
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensiti.
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensiti.
03/05 18:43 EST - seekingalpha.com
Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Kevin Green - Vice President Finance and Chief Financial Officer Vivek Jayaraman - Chief Operating Officer Carol Moore - Senior Vice President of Regulatory Affairs and Quality Conference Call Participants Jacob Johnson - Stephens Emily Christy - Stifel Operator Good day ladies and gentlemen. Thank you for standing by and welcome to the Cerus Corporation's Fourth Quarter and Full Year 2023 Earnings Conference Call.
Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Kevin Green - Vice President Finance and Chief Financial Officer Vivek Jayaraman - Chief Operating Officer Carol Moore - Senior Vice President of Regulatory Affairs and Quality Conference Call Participants Jacob Johnson - Stephens Emily Christy - Stifel Operator Good day ladies and gentlemen. Thank you for standing by and welcome to the Cerus Corporation's Fourth Quarter and Full Year 2023 Earnings Conference Call.
03/05 16:00 EST - businesswire.com
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-quarter 2023 and full-year 2023 total revenue was comprised of (in thousands, except %): Three Months Ended Twelve Months Ended December 31, Change December 31, Change 2023 2022 $ % 2023 2022 $ % Product Revenue $ 46,768 $ 44,034 $ 2,734 6 %.
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-quarter 2023 and full-year 2023 total revenue was comprised of (in thousands, except %): Three Months Ended Twelve Months Ended December 31, Change December 31, Change 2023 2022 $ % 2023 2022 $ % Product Revenue $ 46,768 $ 44,034 $ 2,734 6 %.
02/20 08:30 EST - businesswire.com
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, plea.
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, plea.
02/01 08:30 EST - businesswire.com
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST. A live webcast of the TD Cowen presentation will be available here and the replay will be available on.
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST. A live webcast of the TD Cowen presentation will be available here and the replay will be available on.
01/26 11:50 EST - fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood bought shares of Tesla, Ark 21Shares Bitcoin ETF, and Cerus on Thursday. Tesla shares plunged 12% on Thursday after a troublesome quarterly report.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood bought shares of Tesla, Ark 21Shares Bitcoin ETF, and Cerus on Thursday. Tesla shares plunged 12% on Thursday after a troublesome quarterly report.
01/15 09:30 EST - fool.com
3 Growth Stocks That Could Go Parabolic in 2024
Small- to mid-cap growth stocks largely struggled over the past two years. With the Federal Reserve likely to pivot on interest rates this year, this group may be poised for a trend reversal.
3 Growth Stocks That Could Go Parabolic in 2024
Small- to mid-cap growth stocks largely struggled over the past two years. With the Federal Reserve likely to pivot on interest rates this year, this group may be poised for a trend reversal.
01/08 08:30 EST - businesswire.com
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024. Cerus' unaudited preliminary product revenue for the fourth quarter of 2023 totaled $46.8 million, representing an increase of 6% over the $44.0 million recognized during the fourth quarter of 2022 and 18% sequentially. The Company expects its unaudited preliminary full-year 2023 product.
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024. Cerus' unaudited preliminary product revenue for the fourth quarter of 2023 totaled $46.8 million, representing an increase of 6% over the $44.0 million recognized during the fourth quarter of 2022 and 18% sequentially. The Company expects its unaudited preliminary full-year 2023 product.
11/02 22:52 EST - seekingalpha.com
Cerus Corporation (CERS) Q3 2023 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call.
Cerus Corporation (CERS) Q3 2023 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call.
11/02 18:47 EST - zacks.com
Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates
Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.
Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates
Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.
11/02 16:00 EST - businesswire.com
Cerus Corporation Announces Third Quarter 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. Attended first in-person AABB Annual Meet.
Cerus Corporation Announces Third Quarter 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. Attended first in-person AABB Annual Meet.
11/01 14:46 EST - businesswire.com
Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace
DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace. Bloodbuy's flagship cloud-based platform connect.
Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace
DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace. Bloodbuy's flagship cloud-based platform connect.
10/19 08:30 EST - businesswire.com
Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit th.
Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit th.
10/10 08:30 EST - businesswire.com
Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17. This year's AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. The following is a select list of presentations and abstracts of interest for Cerus. All presentation times are.
Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17. This year's AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. The following is a select list of presentations and abstracts of interest for Cerus. All presentation times are.
09/27 08:30 EST - businesswire.com
Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. “We are excited to welcome Alicia to the Cerus team.
Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. “We are excited to welcome Alicia to the Cerus team.
09/12 08:30 EST - businesswire.com
Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST. A live webcast of the fireside chat will be available at https://wsw.com/webcast/cantor19/cers/2090781. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood s.
Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST. A live webcast of the fireside chat will be available at https://wsw.com/webcast/cantor19/cers/2090781. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood s.